Schrump DS - National Institutes of Health
Mesothelioma Cancer Expert at National Institutes of Health, Bethesda, MD
Mesothelioma Cancer Expert - Schrump DS - Current Listing of Published Papers
The following is a listing of research papers by Schrump DS in the field of mesothelioma cancer.
Articles written by Schrump DS
| Schrump DS, Waheed I. Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas. Semin Cancer Biol. 2001 Feb;11(1):73-80. Pubmed 11243901 Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, MD, 20892, USA. [pop.nci.nih.gov] |
| Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS, Nguyen DM. Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res. 2006 Mar-Apr;26(2A):809-21. Pubmed 16619474 Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. |
| Kassis ES, Zhao M, Hong JA, Chen GA, Nguyen DM, Schrump DS. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J Thorac Cardiovasc Surg. 2006 Feb;131(2):298-306. Epub 2006 Jan 18. Pubmed 16434257 Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Md 20892, USA. |
| Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2005 May;129(5):1010-7. Pubmed 15867774 Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA. |
| Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. Pubmed 15014036 Thoracic Oncology Section, Surgery Branch, and Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1502, USA. |
| Stewart JH 4th, Nguyen DM, Chen GA, Schrump DS. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. J Thorac Cardiovasc Surg. 2002 Feb;123(2):295-302. Pubmed 11828289 National Institutes of Health, National Cancer Institute, Thoracic Oncology Section, Surgery Branch, Bethesda, MD 20892, USA. |
| Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001 Mar-Apr;24(2):151-61. Pubmed 11265773 Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892-1502, USA. |
| Waheed I, Guo ZS, Chen GA, Weiser TS, Nguyen DM, Schrump DS. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells. Cancer Res. 1999 Dec 15;59(24):6068-73. Pubmed 10626792 Thoracic Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. |
